<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000812.v1.p1" parentStudy="phs000812.v1.p1" createDate="2014-10-06" modDate="2014-10-06">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>David Hunter, ScD</td><td>Harvard School of Public Health, Boston, MA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Elio Riboli</td><td>The Imperial College of Science, Technology and Medicine, London, United Kingdom</td></tr>
		<tr><td>Principal Investigator</td><td>Michael Thun</td><td>American Cancer Society, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Susan Gapstur</td><td>American Cancer Society, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Brian Henderson</td><td>University of Southern California, Los Angeles, CA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>The Breast and Prostate Cancer Cohort Consortium (BPC3)</StudyNameEntrez>
	<StudyNameReportPage>The Breast and Prostate Cancer Cohort Consortium (BPC3) GWAS of Aggressive Prostate Cancer and ER- Breast Cancer</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Breast and Prostate Cancer Cohort Consortium (BPC3) was established in 2003 to pool data and biospecimens from nine large prospective cohorts to conduct research on gene-environment interactions in cancer etiology. The BPC3 initially focused on the association of &#62;70 candidate genes in the Steroid Hormone Metabolism and IGF pathways with risk of breast and prostate cancer. The Consortium&#39;s work expanded in 2007 to include genome-wide association studies of estrogen receptor negative (ER-) breast cancer and aggressive prostate cancer. ER- breast cancers have specific epidemiologic characteristics and greater lethality, suggesting ER- breast cancer has a different etiology than ER+ breast cancer. Similarly, aggressive forms of prostate cancer, characterized by extraprostatic extension (Stage C/D) or high histologic grade (Gleason score 8+), differ epidemiologically from the vastly more common indolent forms of prostate cancer and are of the greatest clinical importance. By restricting cases to these specific subtypes, the BPC3 GWAS increased power to detect loci associated with ER- and aggressive prostate cancer (Kraft P and Haiman CA, Nature Genetics 2010 Oct;42:819-20, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Nature+Genetics+2010+Oct%3B42%3A819-20/html/">PMID: 20877320</a> ).</p> <p>The BPC3 GWAS includes the following cohorts: the American Cancer Society Cancer Prevention Study-II (CPS-II); the European Prospective Investigation of Cancer (EPIC); the Physician&#39;s Health Study (PHS); the Nurses&#39; Health Studies I and II (NHS and NHSII); the Health Professionals Follow-up Study (HPFS); the Multiethnic Cohort (MEC); the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; and the Alpha-Tocopherol, Beta-Carotene (ATBC) Study.</p> <p>For the GWAS of ER- cancer, the BPC3 was expanded to include the Polish Breast Cancer Study (PBCS), a population-based case-control study.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>All breast cancer cases were estrogen receptor negative (confirmed through medical records), and all prostate cancer cases either had high histologic grade (Gleason score &#8805; 8) or extraprostatic extension (Stage C/D) (confirmed through medical records). Controls were matched to cases on gender and required to be cancer-free and alive at that matched case&#39;s age at diagnosis.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="22976474"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21743057"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16755295"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Prostatic Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>David Hunter, ScD</AttName>
			<Institution>Harvard School of Public Health, Boston, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Elio Riboli</AttName>
			<Institution>The Imperial College of Science, Technology and Medicine, London, United Kingdom</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Michael Thun</AttName>
			<Institution>American Cancer Society, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Susan Gapstur</AttName>
			<Institution>American Cancer Society, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Brian Henderson</AttName>
			<Institution>University of Southern California, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Montserrat Garcia-Closas</AttName>
			<Institution>The Institute for Cancer Research, London, United Kingdom</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Jonine D. Figueroa</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 CA098233</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 CA098216</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 CA098710</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 CA098758</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Intramural Funds</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="Breast and Prostate Cancer Cohort Consortium (BPC3)" url="http://epi.grants.cancer.gov/BPC3/"/>
	</StudyURLs>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-MDS" longName="General Research Use (MDS)"/>
		<ConsentGroup groupNum="2" shortName="HMB-PUB-MDS" longName="Health/Medical/Biomedical (PUB, MDS)"/>
		<ConsentGroup groupNum="3" shortName="DS-BOED-MDS" longName="Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS)"/>
		<ConsentGroup groupNum="4" shortName="CADM" longName="Cancer in all age groups, other disease in adults only and methods"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000812.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000812.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000812.v1.p1" FileName="eNCI_0212_DUC_8.12.201_updated_04.30.15.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (MDS)</ConsentName>
        <ConsentAbbrev>GRU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Health/Medical/Biomedical (PUB, MDS)</ConsentName>
        <ConsentAbbrev>HMB-PUB-MDS</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor agrees to make results of studies using the data available to the larger scientific community.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="3">
        <ConsentName>Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS)</ConsentName>
        <ConsentAbbrev>DS-BOED-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Breast, Ovarian, or Endometrial Disease.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="4">
        <ConsentName>Cancer in all age groups, other disease in adults only and methods</ConsentName>
        <ConsentAbbrev>CADM</ConsentAbbrev>
        <UseLimitation>The informed consent document signed by the study participants allows use of these data by investigators for discovery and hypothesis generation in the investigation of the genetic contributions to cancer in all age groups and other diseases in adults only, as well as development of novel analytical approaches for GWAS.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="999">
        <ConsentName>Exchange Area</ConsentName>
        <ConsentAbbrev>EA</ConsentAbbrev>
        <UseLimitation>Pre-release exchange area for use by study investigators only.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>

<Analyses>
	<Analysis pha="3863" genomeBuild="38" snpBuild="141" analysisType="">
		<Description>There is evidence that the genetic risk factors for aggressive prostate cancer may be different than those for non-Aggressive disease. We conducted genome-wide association studies of  BPC3 advanced prostate cancer GWAS consist of multiple case-control studies nested within prospective cohorts that were genotyped on HumanHap550, 610 Quad, 660 Quad and 370+240K chips.</Description>
		<Method>categorical analysis</Method>
		<GtyPlatform probeNum="599011" snpBatchId="1048904">
			<Vendor>Illumina</Vendor>
			<VendorURL>Illumina Human610-Quadv1_B chip</VendorURL>
			<Platform>Human610-Quadv1_B</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3864" genomeBuild="38" snpBuild="141" analysisType="">
		<Description>There is evidence that estrogen receptor negative (ER-) breast cancer has a different etiology than ER+ breast cancer. We conducted genome-wide association studies of ER- breast cancer. The BPC3 ER- breast cancer GWAS and  consist of multiple case-control studies nested within prospective cohorts that were genotyped on HumanHap550, 610 Quad, 660 Quad and 317+240K chips.</Description>
		<Method>categorical analysis</Method>
		<GtyPlatform probeNum="599011" snpBatchId="1048904">
			<Vendor>Illumina</Vendor>
			<VendorURL>Illumina Human610-Quadv1_B chip</VendorURL>
			<Platform>Human610-Quadv1_B</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
</Analyses>

</Study>

</Studies>

</GaPExchange>
